- Home
- STEC vs COEP Comparison
STEC vs COEP Comparison
Compare STEC & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- COEP
- Stock Information
- Founded
- STEC 2006
- COEP 2017
- Country
- STEC China
- COEP United States
- Employees
- STEC N/A
- COEP N/A
- Industry
- STEC
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STEC
- COEP Health Care
- Exchange
- STEC NYSE
- COEP Nasdaq
- Market Cap
- STEC 29.7M
- COEP 32.0M
- IPO Year
- STEC 2021
- COEP N/A
- Fundamental
- Price
- STEC $0.97
- COEP $7.66
- Analyst Decision
- STEC
- COEP
- Analyst Count
- STEC 0
- COEP 0
- Target Price
- STEC N/A
- COEP N/A
- AVG Volume (30 Days)
- STEC 12.1K
- COEP 26.4K
- Earning Date
- STEC 07-01-2025
- COEP 08-15-2025
- Dividend Yield
- STEC N/A
- COEP N/A
- EPS Growth
- STEC N/A
- COEP N/A
- EPS
- STEC N/A
- COEP N/A
- Revenue
- STEC $28,023,000.00
- COEP $62,874.00
- Revenue This Year
- STEC $9,392.20
- COEP N/A
- Revenue Next Year
- STEC N/A
- COEP N/A
- P/E Ratio
- STEC N/A
- COEP N/A
- Revenue Growth
- STEC 50.79
- COEP N/A
- 52 Week Low
- STEC $0.20
- COEP $2.31
- 52 Week High
- STEC $3.25
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- STEC 43.73
- COEP 33.94
- Support Level
- STEC $0.97
- COEP $7.50
- Resistance Level
- STEC $1.02
- COEP $8.62
- Average True Range (ATR)
- STEC 0.08
- COEP 0.48
- MACD
- STEC 0.00
- COEP -0.15
- Stochastic Oscillator
- STEC 14.78
- COEP 3.77
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.